Dr. Fischer is a Board-Certified Endocrinologist, specializing in Internal Medicine with an expertise in several areas, including Type 2 diabetes mellitus, adult obesity, diseases of the pituitary and the thyroid glands. He is a highly experienced physician with more than 35 years in the field of Endocrinology/Diabetes/Metabolism, both in private practice and in research. After receiving his Bachelor of Science, Magna Cum Laude, from the University of Pennsylvania in 1973, he received his medical degree from the highly rated Thomas Jefferson University Medical School in 1977. He completed his Fellowship in Endocrinology at George Washington University Medical Center in 1982.
He joined the Diabetes & Glandular Disease Clinic in San Antonio, Texas as first partner in July 1982. He is highly regarded by his patients, and is the recipient of numerous awards. He is a published author and lecturer, having numerous articles in peer-reviewed journals. Accomplished in the field of research, Dr. Fischer has served on several Advisory Boards, most recently Glooko, Inc. He has been an Adjunct Associate Professor/Clinical Instructor of Medicine/Endocrinology for the University of Texas Health Science Center at San Antonio for numerous years, and is an active member of several esteemed professional groups, including the American Association of Clinical Endocrinologists, The American Diabetes Association, and The Endocrine Society, to name a few.
Dr. Fischer has raised awareness for people with intellectual disabilities by sponsoring and encouraging his clinic employees and their families to participate in various 5K Walks & Runs. He has a keen interest in the expanding technology of diabetes care, including cloud-based systems, and looks forward to digital health solutions changing the face of chronic disease management for patients living with chronic diseases such as diabetes. He and his partners at DGD Clinic are excited about the new FDA-approved smart phone apps that titrate, or make continuous insulin adjustments for patients with Type 1 and Type 2 diabetes. Equally exciting for the clinic is the arrival of a new, groundbreaking hybrid closed loop insulin pump. This groundbreaking technology will simplify and improve diabetes management with the use of smart algorithms, resulting in greater glucose control with reduced user input.